MX421763B - Metodos y composiciones que comprenden proteina d tensoactiva (sp-d) - Google Patents

Metodos y composiciones que comprenden proteina d tensoactiva (sp-d)

Info

Publication number
MX421763B
MX421763B MX2020010030A MX2020010030A MX421763B MX 421763 B MX421763 B MX 421763B MX 2020010030 A MX2020010030 A MX 2020010030A MX 2020010030 A MX2020010030 A MX 2020010030A MX 421763 B MX421763 B MX 421763B
Authority
MX
Mexico
Prior art keywords
protein
surfactin
compositions
methods
rhsp
Prior art date
Application number
MX2020010030A
Other languages
English (en)
Other versions
MX2020010030A (es
Inventor
Derrick S Katayama
Giovanni M Pauletti
Jan Susan Rosenbaum
Mark Cornell Manning
Ryan Holcomb
Shawn Grant
Original Assignee
Airway Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Airway Therapeutics Inc filed Critical Airway Therapeutics Inc
Publication of MX2020010030A publication Critical patent/MX2020010030A/es
Publication of MX421763B publication Critical patent/MX421763B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende proteína D tensoactiva humana recombinante (rhSP-D) o un fragmento activo de la misma, un amortiguador de histidina, una azúcar y una sal de calcio.
MX2020010030A 2018-03-29 2019-03-27 Metodos y composiciones que comprenden proteina d tensoactiva (sp-d) MX421763B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650142P 2018-03-29 2018-03-29
PCT/US2019/024305 WO2019191247A1 (en) 2018-03-29 2019-03-27 Methods and compositions comprising surfactant protein d (sp-d)

Publications (2)

Publication Number Publication Date
MX2020010030A MX2020010030A (es) 2021-01-15
MX421763B true MX421763B (es) 2025-03-14

Family

ID=68060728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010030A MX421763B (es) 2018-03-29 2019-03-27 Metodos y composiciones que comprenden proteina d tensoactiva (sp-d)

Country Status (12)

Country Link
US (1) US12491234B2 (es)
EP (1) EP3774875B1 (es)
JP (1) JP7797098B2 (es)
KR (1) KR102917619B1 (es)
CN (1) CN112119088A (es)
AU (1) AU2019243707B2 (es)
BR (1) BR112020019861A2 (es)
CA (1) CA3095043A1 (es)
IL (1) IL277468B2 (es)
MX (1) MX421763B (es)
RU (1) RU2020131642A (es)
WO (1) WO2019191247A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277469B2 (en) 2018-03-29 2024-11-01 Airway Therapeutics Inc Systems and methods for characterizing surfactant protein d (sp-d) oligomers
AU2021258178A1 (en) * 2020-04-22 2022-11-17 Airway Therapeutics, Inc. Use of surfactant protein D to treat viral infections
CN118382805A (zh) * 2022-01-31 2024-07-23 积水医疗株式会社 肺表面活性蛋白的免疫测定方法和免疫测定试剂
JPWO2023145916A1 (es) * 2022-01-31 2023-08-03
AU2024373079A1 (en) 2023-11-02 2025-10-23 Airway Therapeutics, Inc. Methods for treating premature newborn infants by administration of recombinant human surfactant protein d (rhsp-d)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838428B2 (en) * 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US8933032B2 (en) * 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
JP3573330B2 (ja) 1999-07-22 2004-10-06 ヤマサ醤油株式会社 安定化された抗原含有水溶液
JP3418827B2 (ja) 2000-03-15 2003-06-23 ミネベア株式会社 Ｍｎ−Ｚｎフェライトおよびその製造方法
AU2002337312A1 (en) 2001-10-25 2003-05-06 Medical Research Council Molecules
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
CN102947335B (zh) 2010-04-15 2018-11-06 基因泰克公司 抗多聚遍在蛋白抗体及使用方法
TR201911076T4 (tr) * 2011-01-05 2019-08-21 Prenatal Int Gmbh Klorür içeriği azaltılmış fosfolipit içeren veya içermeyen hipotonik sulu bileşim.
US20120220531A1 (en) * 2011-02-04 2012-08-30 Cincinnati Children's Hospital Medical Center Surfactant protein d for the treatment of disorders associated with lung injury
BR112014011345A2 (pt) 2011-11-11 2017-05-16 Philip Morris Products Sa partículas tipo vírus da influenza (vlps) compreendendo nicotiana tabacum produzida por hemaglutinina
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
SMT202000058T1 (it) 2012-10-26 2020-03-13 Oncopeptides Ab Preparazioni liofilizzate di melfalan flufenammide
ES2572919T3 (es) * 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
MA44252A (fr) * 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
CN112040967A (zh) 2017-09-06 2020-12-04 气道治疗公司 用于制备表面活性蛋白d(sp-d)的方法、组合物和细胞
EP3679066A4 (en) 2017-09-06 2021-06-09 Airway Therapeutics, Inc. METHOD AND COMPOSITIONS FOR MANUFACTURING SURFACTANT PROTEIN D (SP-D)
IL277469B2 (en) 2018-03-29 2024-11-01 Airway Therapeutics Inc Systems and methods for characterizing surfactant protein d (sp-d) oligomers

Also Published As

Publication number Publication date
EP3774875C0 (en) 2026-03-18
AU2019243707B2 (en) 2023-12-07
US12491234B2 (en) 2025-12-09
IL277468B2 (en) 2024-09-01
KR102917619B1 (ko) 2026-01-27
RU2020131642A (ru) 2022-04-29
EP3774875A1 (en) 2021-02-17
EP3774875A4 (en) 2022-01-12
CA3095043A1 (en) 2019-10-03
AU2019243707A1 (en) 2020-10-15
CN112119088A (zh) 2020-12-22
US20210121536A1 (en) 2021-04-29
KR20210007961A (ko) 2021-01-20
JP7797098B2 (ja) 2026-01-13
IL277468A (en) 2020-11-30
MX2020010030A (es) 2021-01-15
EP3774875B1 (en) 2026-03-18
BR112020019861A2 (pt) 2021-01-05
WO2019191247A1 (en) 2019-10-03
JP2021519757A (ja) 2021-08-12
IL277468B1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
MX421763B (es) Metodos y composiciones que comprenden proteina d tensoactiva (sp-d)
MX2022006760A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2020008219A (es) Formulacion farmaceutica de ph bajo.
PE20220256A1 (es) Sistemas de casx artificiales
PE20220940A1 (es) Proteinas quimericas insecticidas novedosas toxicas o inhibidoras de plagas de lepidopteros
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
EA201792245A1 (ru) Биоконъюгаты и их применения
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
MX381232B (es) Formulación de anticuerpos.
BR112019023846A2 (pt) composição farmacêutica de anticorpo de pd-l1 e uso da mesma
EA201991511A1 (ru) Кристаллическая структура гремлин-1 и ингибирующее антитело
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
EA201992278A1 (ru) Способы и композиции для снижения иммуногенности
CL2020001307A1 (es) Formulación.
ECSP20083339A (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
EA201791716A1 (ru) Фармацевтический состав
CY1123728T1 (el) (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ
PE20170287A1 (es) Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso
IL283229A (en) High concentration protein formulation
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
EA202092335A1 (ru) Композиции на основе эренумаба и пути их применения
MX2019002248A (es) Proteina de union al factor h modificada.